Mumbai February 10, 2013:- After the US Food and Drug Administration (USFDA) raised concerns over Ranbaxy’s largest drug ingredient plant at Toansa, many questions regarding the GMP compliance have come up. The company is making every attempt to investigate these issues and aims at resolving them.
During the company’s internal investigations, certain preliminary findings have called attention. These findings point towards a possibility that some of the good manufacturing practice (GMP) violations that the FDA inspectors observed at the Toansa plant could have been framed by some dissatisfied employees. This needs further investigations before concluding anything. – GMP
New Delhi, January 10, 2025: Arya Vaidya Pharmacy (Coimbatore) Ltd. (AVP), a pioneer in Ayurvedic healthcare…
By Srinath Rao, Senior Vice President, CitiusTech A few decades back, the purpose of watches…
Pharmapack Europe: 'Basel the best location for drug device innovation in Europe thanks to combination…
New Delhi, January 07, 2025: HMP virus can travel to the brain, or it can…
~ Co-authored by Dr Sanjith Saseedharan, Director-Critical Care, S. L. Raheja Hospital- A Fortis Associate…
Patients Embrace Flexibility with 37% of Online Doctor Consultations now happening even After 6 PM,…